Merck KGaA in push to become twice as productive in drug development

Reuters

Published Nov 21, 2022 07:18AM ET

FRANKFURT (Reuters) - Germany's Merck KGaA on Monday said it aims to double the productivity of its research and development into oncology, neurology and immunology treatments.